BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on July 6, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 33,135 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 22,085 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 11,050 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan").
hello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
